Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2 Placebo Controlled, Double Blinded Study on the Efficacy and Safety of BXQ-350 in Combination With mFOLFOX7 and Bevacizumab in Newly Diagnosed Metastatic Colorectal Carcinoma

NCT05322590 is registered in ClinicalTrials.gov with Bexion Pharmaceuticals, Inc. as lead sponsor.

NCT NCT05322590
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05322590 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2 Placebo Controlled, Double Blinded Study on the Efficacy and Safety of BXQ-350 in Combination With mFOLFOX7 and Bevacizumab in Newly Diagnosed Metastatic Colorectal Carcinoma
Lead sponsor
Bexion Pharmaceuticals, Inc.
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
January 9, 2023
Completion date
April 30, 2029
Enrollment
195 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic colorectal carcinoma, neuropathy